Human anti-IL-23 antibodies, compositions, methods and uses
A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
1. A prefilled syringe containing a liquid pharmaceutical formulation of an isolated IL-23p19 antibody, comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:
a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50;
a CDRL2 amino acid sequence of SEQ ID NO:56; and
a CDRL3 amino acid sequence of SEQ ID NO:73,
said heavy chain variable region comprising:
a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:5;
a CDRH2 amino acid sequence of SEQ ID NO:20; and
a CDRH3 amino acid sequence of SEQ ID NO:44.
2. The prefilled syringe of claim 1 , wherein the pH of the formulation is 5.8.
3. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises histidine.
4. A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising at least one member selected from the group consisting of a light chain variable region having the amino acid sequence of SEQ ID NO:116, a heavy chain variable region having the amino acid sequence of SEQ ID NO:106, and a heavy chain variable region having the amino acid sequence of SEQ ID NO:106 with up to three substitutions from residues 50-66 of the amino acid sequence of SEQ ID NO: 106.
5. The prefilled syringe of claim 4 , wherein the pH of the formulation is 5.8.
6. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises histidine.
7. A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:116 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:106.
8. The prefilled syringe of claim 7 , wherein the pH of the formulation is 5.8.
9. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises histidine.
10. A prefilled syringe containing a liquid pharmaceutical formulation of an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:116, a heavy chain variable region having the amino acid sequence of SEQ ID NO:106, wherein the liquid pharmaceutical formulation comprises histidine and the pH of the formulation is 5.8.
11. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises sucrose.
12. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises poly sorbate 80.
13. The prefilled syringe of claim 2 , wherein the liquid pharmaceutical formulation comprises water.
14. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises sucrose.
15. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises poly sorbate 80.
16. The prefilled syringe of claim 5 , wherein the liquid pharmaceutical formulation comprises water.
17. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises sucrose.
18. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises poly sorbate 80.
19. The prefilled syringe of claim 7 , wherein the liquid pharmaceutical formulation comprises water.